Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Binimetinib with nivolumab or nivolumab plus ipilimumab in previously treated MSS RAS-mutant metastatic colorectal cancer
NL-OMON50266Phase 2Completed
- Sponsor
- Array BioPharma
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of binimetinib, nivolumab and ipilimumab in colorectal cancer (CRC) (4 arms), sponsored by Array BioPharma. Primary endpoints: Incidence of dose-limiting toxicities with binimetinib plus nivolumab, Incidence of dose-limiting toxicities with binimetinib plus nivolumab plus ipilimumab and 1 more. Started Oct 2018; status: completed.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON50266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50266.